An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

Giorgio V Scagliotti; Enriqueta Felip; Benjamin Besse; Joachim von Pawel; Anders Mellemgaard; Martin Reck; Lionel Bosquee; Christos Chouaid; Pilar Lianes-Barragán; Elaine M Paul; Rodrigo Ruiz-Soto; Entisar Sigal; Lone H Ottesen; Thierry Lechevalier

doi:10.1097/JTO.0000000000000005

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

Giorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, Joachim von Pawel, Anders Mellemgaard, Martin Reck, Lionel Bosquee, Christos Chouaid, Pilar Lianes-Barragán, Elaine M Paul, Rodrigo Ruiz-Soto, Entisar Sigal, Lone H Ottesen, Thierry Lechevalier

Oncology

33 Citations (Scopus)

Abstract

This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous non-small-cell lung cancer.

Original language	English
Journal	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Volume	8
Issue number	12
Pages (from-to)	1529-37
Number of pages	9
ISSN	1556-0864
DOIs	https://doi.org/10.1097/JTO.0000000000000005
Publication status	Published - Dec 2013

Access to Document

10.1097/JTO.0000000000000005

Cite this

Scagliotti, G. V., Felip, E., Besse, B., von Pawel, J., Mellemgaard, A., Reck, M., Bosquee, L., Chouaid, C., Lianes-Barragán, P., Paul, E. M., Ruiz-Soto, R., Sigal, E., Ottesen, L. H., & Lechevalier, T. (2013). An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8(12), 1529-37. https://doi.org/10.1097/JTO.0000000000000005

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. / Scagliotti, Giorgio V; Felip, Enriqueta; Besse, Benjamin et al.

In: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Vol. 8, No. 12, 12.2013, p. 1529-37.

Research output: Contribution to journal › Journal article › Research › peer-review

Scagliotti, GV, Felip, E, Besse, B, von Pawel, J, Mellemgaard, A, Reck, M, Bosquee, L, Chouaid, C, Lianes-Barragán, P, Paul, EM, Ruiz-Soto, R, Sigal, E, Ottesen, LH & Lechevalier, T 2013, 'An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer', Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 8, no. 12, pp. 1529-37. https://doi.org/10.1097/JTO.0000000000000005

Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M et al. An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Dec;8(12):1529-37. https://doi.org/10.1097/JTO.0000000000000005

Scagliotti, Giorgio V ; Felip, Enriqueta ; Besse, Benjamin et al. / An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. In: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 ; Vol. 8, No. 12. pp. 1529-37.

@article{180ca70891cc42a39ef6e42f8b39267d,

title = "An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer",

abstract = "This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous non-small-cell lung cancer.",

author = "Scagliotti, {Giorgio V} and Enriqueta Felip and Benjamin Besse and {von Pawel}, Joachim and Anders Mellemgaard and Martin Reck and Lionel Bosquee and Christos Chouaid and Pilar Lianes-Barrag{\'a}n and Paul, {Elaine M} and Rodrigo Ruiz-Soto and Entisar Sigal and Ottesen, {Lone H} and Thierry Lechevalier",

note = "Department of Clinical and Biological Sciences, University of Turin, Orbassano, Torino, Italy; †Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; ‡Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France; §Asklepios Clinic, Asklepios Fachkliniken M{\"u}nchen-Gauting, Gauting, Germany; ‖Department of Oncology, Herlev Hospital, Onkologisk afdeling, Herlev, Denmark; ¶Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; #Department of Respiratory Medicine, Centre Hospitalier Universitaire de Liege, Liege, Belgium; **Department of Respiratory Medicine, Hopital Saint-Antoine, Paris Cedex, France; ††Department of Medical Oncology, Hospital de Mataro, Mataro, Spain; and ‡‡Oncology Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina; Collegeville, Philadelphia, Pennsylvania; and Uxbridge, United Kingdom.",

year = "2013",

month = dec,

doi = "10.1097/JTO.0000000000000005",

language = "English",

volume = "8",

pages = "1529--37",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Lippincott Williams & Wilkins",

number = "12",

}

TY - JOUR

T1 - An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

AU - Scagliotti, Giorgio V

AU - Felip, Enriqueta

AU - Besse, Benjamin

AU - von Pawel, Joachim

AU - Mellemgaard, Anders

AU - Reck, Martin

AU - Bosquee, Lionel

AU - Chouaid, Christos

AU - Lianes-Barragán, Pilar

AU - Paul, Elaine M

AU - Ruiz-Soto, Rodrigo

AU - Sigal, Entisar

AU - Ottesen, Lone H

AU - Lechevalier, Thierry

N1 - Department of Clinical and Biological Sciences, University of Turin, Orbassano, Torino, Italy; †Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; ‡Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France; §Asklepios Clinic, Asklepios Fachkliniken München-Gauting, Gauting, Germany; ‖Department of Oncology, Herlev Hospital, Onkologisk afdeling, Herlev, Denmark; ¶Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; #Department of Respiratory Medicine, Centre Hospitalier Universitaire de Liege, Liege, Belgium; **Department of Respiratory Medicine, Hopital Saint-Antoine, Paris Cedex, France; ††Department of Medical Oncology, Hospital de Mataro, Mataro, Spain; and ‡‡Oncology Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina; Collegeville, Philadelphia, Pennsylvania; and Uxbridge, United Kingdom.

PY - 2013/12

Y1 - 2013/12

N2 - This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous non-small-cell lung cancer.

AB - This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous non-small-cell lung cancer.

U2 - 10.1097/JTO.0000000000000005

DO - 10.1097/JTO.0000000000000005

M3 - Journal article

C2 - 24389434

VL - 8

SP - 1529

EP - 1537

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 12

ER -

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

Abstract

Access to Document

Fingerprint

Cite this